Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28596004 | 0.95 | APEX1 (0.32) | — | |
| Sulfuric Acid SCHEMBL4057330 | 0.88 | BBOX1 (0.35) | — | |
| SCHEMBL714615 | 0.84 | MEN1 (0.38) | LMNA | |
| SCHEMBL5154412 | 0.82 | MEN1 (0.42) | LMNA | |
| Hydrochloric Acid SCHEMBL28916544 | 0.82 | APEX1 (0.40) | LMNA | |
| SCHEMBL12047846 | 0.80 | MEN1 (0.46) | LMNA | |
| SCHEMBL370815 | 0.79 | ADRB2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL2021971 | 0.79 | APEX1 (0.48) | LMNA | |
| Hydrochloric Acid SCHEMBL28686190 | 0.79 | MEN1 (0.44) | LMNA | |
| SCHEMBL3264796 | 0.74 | MEN1 (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655824-B2 | Use of diphenylmethane derivatives as tyrosinase inhibitors | SYMRISE AG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-1959915-B1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE AG (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-8911795-B2 | Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching | SYMRISE AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8409552-B2 | Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds | SYMRISE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | SYMRISE AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-8203016-B2 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE AG (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-2023910-A1 | AH RECEPTOR ANTAGONISTS | Symrise GmbH & Co. KG (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1959915-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | Symrise GmbH & Co. KG (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1893161-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND COOLING AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | Symrise GmbH & Co. KG (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007128723-A1 | AH RECEPTOR ANTAGONISTS | SYMRISE GMBH & CO. KG (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007062957-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-20070098655-A1 | Use of diphenylmethane derivatives as tyrosinase inhibitors | SYMRISE AG (DE) | 2007-05-03 | — | — | US | disclosed |
| WO-2006134013-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND COOLING AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134120-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND COOLING AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060089413-A1 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE GMBH & CO. KG (DE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089413-A1 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | HRH1, CMA1, HRH2 | LMNA 3937/4885 |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | CMA1, TPSAB1, HRH1 | LMNA 3939/4885 |
| US-20070098655-A1 | Use of diphenylmethane derivatives as tyrosinase inhibitors | TYR, DPM1, DDT | LMNA 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.